Skip to Content

Pomalyst Approval History

  • FDA approved: Yes (First approved February 8th, 2013)
  • Brand name: Pomalyst
  • Generic name: pomalidomide
  • Dosage form: Capsules
  • Company: Celgene Corporation
  • Treatment for: Multiple Myeloma

Pomalyst (pomalidomide) is a thalidomide analogue indicated for the treatment of patients with multiple myeloma.

Development History and FDA Approval Process for Pomalyst

Feb  8, 2013Approval FDA Approves Pomalyst for Advanced Multiple Myeloma
Oct  3, 2012Celgene Corporation Provides Update on FDA Advisory Committee for Pomalidomide
Apr 27, 2012The International Myeloma Foundation Says Pomalidomide, an Important New Drug for Patients, Has Been Submitted for FDA Approval

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.